This ar cle includes a [French andSpanish] transla on, available in the Suppor ng Informa on sec on.Post publica on no ce: 23 August 2017, a er fi rst online publica on: French and Spanish transla ons are made available in the Suppor ng Informa on.
AbstractWe already know what causes cervical cancer, how to prevent it, and how to treat it, even in resource-constrained se ngs. Inequitable access to human papillomavirus vaccine for girls and screening and precancer treatment for women in low-and middleincome countries is unacceptable on ethical, social, and financial grounds. The burden of cervical cancer falls on the poor and extends beyond the narrow bounds of the family, affec ng na onal economic development and community life, as family resources are drained and poverty ghtens its grip. Proven solu ons are available and the priori es for the next few years are clear, as shown by the papers in this Supplement.Sustained poli cal commitment and strategic investments in cervical cancer prevenon can not only save millions of lives over the next 10 years, but can also pave the way for the broader fight against all cancers.
K E Y W O R D SCervical cancer ; Disease elimina on ; Low-income countries ; Preven on
| INTRODUCTIONWe already know what causes cervical cancer, how to prevent it, and how to treat it, even in resource-constrained se ngs. Yet, sadly, every two minutes a woman dies of this disease. The global divide in incidence and mortality for cervical cancer could hardly be more stark. The vast majority of women who develop and die of cervical cancer live in low-and middle-income countries (LMICs), where access to primary and secondary preven on-and care for women with invasive disease, including pallia ve care-remains profoundly limited. The problem fundamentally is social and economic inequality-the solu on is, in large part, sustained poli cal commitment.If the current genera on of young adolescent girls can be vaccinated against human papillomavirus (HPV), in 20-30 years as they reach the ages when precancerous lesions would normally appear and take hold, they can expect to be nearly free of the threat of cervical cancer. The good news about cross-protec on against HPV types not included in the vaccine and herd immunity for those who missed being vaccinated 1,2 and the recent licensing of a 9-valent vaccine that protects against 90% of the types causing cervical cancer suggests we may be closer to elimina on of this disease than we dreamed possible 10 years ago when the vaccine was first introduced. 3 Despite this exci ng prospect and the hard work it will take to make widespread HPV vaccina on a reality, we cannot forget the millions of adult women and older adolescent girls who were beyond the priority age for vaccina on when it became available in their communi es. These women deserve a chance to have the protec on that screening and preven ve treatment (for precancer) provides-the protec on women in wealthy countries have benefitted from for decades. Arguments to ra onalize this gross inequity of acces...